Clinical trial MAHOGANY
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (BGB-3111-308)
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | BeiGene |
| EudraCT Identifier | 2022-502548-12-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05100862 |
| Inclusion criteria | Patients must have an investigator-assessed diagnosis of R/R indolent lymphoma, defined in this study as Grade 1, 2, or 3a FL or MZL; must have been previously treated for their lymphoma with at least one line of systemic therapy, including anti-CD20 mono |
| Last update |